Immuneering Corporation Goes Public with $112M IPO

Choate assisted Immuneering Corporation with handling its platform IP in its $112.5M IPO. The Choate IP team has supported Immuneering as IP counsel since its $20M Series A funding round in January 2020. A portion of the proceeds from the IPO will be used to bring Immuneering’s lead candidate, a dual-MEK inhibitor dubbed IMM-1-104, into the clinic for advanced solid tumors in patients harboring RAS mutations. Immuneering plans on submitting an Investigational New Drug (IND) Application for this candidate in the first quarter of 2022.